Na Yang

Prof. Na Yang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
YFYing Feng
Ying Feng
RGRuiying Guo
Ruiying Guo
XSXiaoyu Sang
Xiaoyu Sang
XZXiaohan Zhang
Xiaohan Zhang
MLMeiqi Li
Meiqi Li
Sarah JiangSarah Jiang
Sarah Jiang
Sarcocystosis is an intracellular parasitic disease caused by Sarcocystis spp. that has a worldwide prevalence. Symptoms of the disease include diarrhea and muscle pain. The disease poses a threat to the health of animals. The aim of this review is to investigate the global prevalence of Sarcocystis infection in sheep and goats during 2013–2022. We searched five databases: Web of Science, Science Direct, PubMed, Scopus, and Google Scholar. A total of 36 articles containing 44 datasets met the criteria and were included in the study. The total infection rates of Sarcocystis in sheep and goats were 66.3% (95% CI, 51.79–79.38%) and 52.1% (95% CI, 29.45–74.23%), respectively. It was found that Sarcocystis species tend to have a host species preference. Coinfection of S. tenella and S. arieticanis often occurred in sheep, and goats were frequently infected with S. capracanis. Age and sex were identified as risk factors for Sarcocystis infection in sheep and goats. The infection rates of female and male animals were significantly different, with females having a higher infection rate. Age-adjusted analysis showed that infection rates in animals older than one year were higher than in animals younger than one year. This study unveiled the global distribution of Sarcocystis and sheds light on its transmission in sheep and goats.

2 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
XLXiang Li
Xiang Li
WYWei Yuan
Wei Yuan
THTing He
Ting He
RGRuiying Guo
Ruiying Guo
XDXiuxian Du
Xiuxian Du
XSXiaoyu Sang
Xiaoyu Sang
Toxoplasmosis is a major worldwide protozoan zoonosis. The surface antigen 1 (SAG1) of Toxoplasma gondii (T. gondii) has always been recognized as an ideal vaccine candidate antigen. However, the intact and soluble SAG1 protein is usually difficult to acquire in vitro, which is unfavorable for employing the recombinant protein as a vaccine candidate antigen. In the present study, we obtained the full-length SAG1 recombinant protein in soluble form by Escherichia coli Transetta (DE3) cells under optimized expression conditions. The immunogenicity and protective ability of this recombinant protein against T. gondii acute infection were evaluated in a mouse model. Monitoring changes in serum antibody levels and types, the presence of cytokines, and the rate of lymphocyte proliferation in vaccinated mice were used to assess humoral and cellular immune responses. Additional assessments were performed to determine the protective potency of the recombinant protein in combating T. gondii RH tachyzoites. It was found that the titers of both IgG2a and IgG2b were considerably greater in the immunized mice compared to the titers of IgG1 and IgG3. The levels of Th1-type cytokines (IFN-γ, IL-12p70, IL-2, and TNF-α) and Th2-type cytokines (IL-10) significantly increased when splenocytes from immunological group mice were treated with T. gondii lysate antigen. Compared to the control group, a recombinant protein substantially increased the longevity of infected mice, with an average death time prolonged by 14.50 ± 0.34 days (p < 0.0001). These findings suggest that the full-length and soluble SAG1 recombinant protein produced potent immune responses in mice and could be a preferred subunit vaccine candidate for T. gondii, offering a feasible option for vaccination against acute toxoplasmosis.

2 July 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
XSXiaoyu Sang
Xiaoyu Sang
XLXiang Li
Xiang Li
RCRan Chen
Ran Chen
YFYing Feng
Ying Feng
THTing He
Ting He
NYNa Yang
Na Yang
Toxoplasma gondii (T. gondii) has many intermediate hosts, obligately invades nucleated cells, and seriously threatens human and animal health due to a lack of effective drugs and vaccines. Sialic acid-binding protein 1 (SABP1) is a novel invasion-related protein that, like surface antigen 1 (SAG1), is found on the plasma membrane of T. gondii. To investigate the immunogenicity and protective efficacy of DNA vaccines expressing SABP1 and SAG1 proteins against T. gondii acute infection, the recombinant plasmids pVAX1-SABP1 and pVAX1-SAG1 were produced and administered intramuscularly in Balb/c mice. Serum antibody levels and subtypes, lymphocyte proliferation, and cytokines were used to assess immunized mice’s humoral and cellular immune responses. Furthermore, the ability of DNA vaccines to protect mice against T. gondii RH tachyzoites was tested. Immunized mice exhibited substantially higher IgG levels, with IgG2a titers higher than IgG1. When the immune group mice’s splenocytes were stimulated with T. gondii lysate antigen, Th1-type cytokines (IL-12p70, IFN-γ, and IL-2) and Th2-type cytokine (IL-4) increased significantly. The combined DNA vaccine significantly increased the immunized mouse survival compared to the control group, with an average death time extended by 4.33 ± 0.6 days (p < 0.0001). These findings show that DNA vaccines based on the SABP1 and SAG1 genes induced robust humoral and cellular immunity in mice, effectively protecting against acute toxoplasmosis and potentially serving as a viable option for vaccination to prevent T. gondii infection.

Verified
Journal Article
Open access
PDF file
MLMeiqi Li
Meiqi Li
XSXiaoyu Sang
Xiaoyu Sang
XZXiaohan Zhang
Xiaohan Zhang
XLXiang Li
Xiang Li
YFYing Feng
Ying Feng
Sarah JiangSarah Jiang
Sarah Jiang
Toxoplasma gondii is an obligate protozoon that can infect all warm-blooded animals including humans. T. gondii afflicts one-third of the human population and is a detriment to the health of livestock and wildlife. Thus far, traditional drugs such as pyrimethamine and sulfadiazine used to treat T. gondii infection are inadequate as therapeutics due to relapse, long treatment period, and low efficacy in parasite clearance. Novel, efficacious drugs have not been available. Lumefantrine, as an antimalarial, is effective in killing T. gondii but has no known mechanism of action. We combined metabolomics with transcriptomics to investigate how lumefantrine inhibits T. gondii growth. We identified significant alternations in transcripts and metabolites and their associated functional pathways that are attributed to lumefantrine treatment. RH tachyzoites were used to infect Vero cells for three hours and subsequently treated with 900 ng/mL lumefantrine. Twenty-four hours post-drug treatment, we observed significant changes in transcripts associated with five DNA replication and repair pathways. Metabolomic data acquired through liquid chromatography-tandem mass spectrometry (LC-MS) showed that lumefantrine mainly affected sugar and amino acid metabolism, especially galactose and arginine. To investigate whether lumefantrine damages T. gondii DNA, we conducted a terminal transferase assay (TUNEL). TUNEL results showed that lumefantrine significantly induced apoptosis in a dose-dependent manner. Taken together, lumefantrine effectively inhibited T. gondii growth by damaging DNA, interfering with DNA replication and repair, and altering energy and amino acid metabolisms.

22 October 2020 in Parasitology
Verified
Journal Article
Open access
PDF file
DWDawei Wang
Dawei Wang
MXMengen Xing
Mengen Xing
SESaeed El-Ashram
Saeed El-Ashram
YDYingying Ding
Yingying Ding
XZXiao Zhang
Xiao Zhang
NYNa Yang
Na Yang
Toxoplasma gondii is an obligate intracellular protozoan parasite, which can infect almost all warm-blooded animals, including humans, leading to toxoplasmosis. Currently, the effective treatment for human toxoplasmosis is the combination of sulphadiazine and pyrimethamine. However, both drugs have serious side-effects and toxicity in the host. Therefore, there is an urgent need for the discovery of new anti-T. gondii drugs with high potency and less or no side-effects. Our findings suggest that lumefantrine exerts activity against T. gondii by inhibiting its proliferation in Vero cells in vitro without being toxic to Vero cells (P ≤ 0.01). Lumefantrine prolonged mice infected with T. gondii from death for 3 days at the concentration of 50 μg L−1 than negative control (phosphate-buffered saline treated only), and reduced the parasite burden in mouse tissues in vivo (P ≤ 0.01; P ≤ 0.05). In addition, a significant increase in interferon gamma (IFN-γ) production was observed in high-dose lumefantrine-treated mice (P ≤ 0.01), whereas interleukin 10 (IL-10) and IL-4 levels increased in low-dose lumefantrine-treated mice (P ≤ 0.01). The results demonstrated that lumefantrine may be a promising agent to treat toxoplasmosis, and more experiments on the protective mechanism of lumefantrine should be undertaken in further studies.

6 September 2023 in Animal Diseases
Verified
Journal Article
Open access
CLChenghuan Li
Chenghuan Li
XZXiaohan Zhang
Xiaohan Zhang
XSXiaoyu Sang
Xiaoyu Sang
YHYanhong He
Yanhong He
SESaeed Ei-Ashram
Saeed Ei-Ashram
NYNa Yang
Na Yang